Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
Anthony V MoormanGrace AntonyRachel WadeEllie R ButlerAmir EnshaeiChristine J HarrisonJohn P MoppettRachael HoughClare RowntreeJeremy HancockNicholas GouldenSujith SamarasingheAjay VoraPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Long-term outcomes of the UKALL2003 trial confirm that low-risk patients can safely de-escalate therapy, while intensified therapy benefits patients with high-risk cytogenetics. Regardless of prognosis, the time to cure is similar across risk groups. This will facilitate communication to patients and families who pose the question "When am I/is my child cured?"
Keyphrases
- end stage renal disease
- acute lymphoblastic leukemia
- risk factors
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- study protocol
- randomized controlled trial
- peritoneal dialysis
- mental health
- stem cells
- phase ii
- phase iii
- patient reported outcomes
- acute myeloid leukemia
- bone marrow
- cell therapy
- allogeneic hematopoietic stem cell transplantation
- open label
- early life